Please assess the completion status of the following clinical trial:

Trial Title: TBE Seropersistence up to 10 Years After First Booster in Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subjects who participated in the first and second precursor studies will be eligible for participation in this study if:~* they understand the nature of the study, agree to its provisions and provide written informed consent~* they received the first booster vaccination with FSME-IMMUN 0.5ml during the first precursor study and did not receive a second booster vaccination in the second precursor study~* blood was drawn after their first booster vaccination in the first precursor study~Exclusion Criteria:~Subjects will be excluded from participation in this study if they:~* received any TBE vaccination since their first booster vaccination with FSME-IMMUN 0.5ml~* have a history of infection with or vaccination against other flaviviruses (e.g. dengue fever, yellow fever, Japanese B-encephalitis) since their first booster vaccination with FSME-IMMUN 0.5ml~* are known to be HIV positive since their first booster vaccination with FSME-IMMUN 0.5ml~* have a known or suspected problem with drug or alcohol abuse

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Seropersistence evaluation + 2nd booster vaccination (Type: EXPERIMENTAL): Blood will be drawn to assess the seropersistence of TBE virus antibodies at 82, 94, 106 and 118 months after the first booster vaccination with FSME-IMMUN 0.5ml administered during the first precursor study. Timing of the second booster vaccination will depend on the level of serum TBE antibodies observed during the study. Blood will be drawn 21 - 35 days after vaccination to assess the booster response.

Based on this trial design, predict the completion outcome and termination type (if applicable).